CMS Entry id: 2709 | Channel: Blog landing page | Template: blog/index

Login
Facebook YouTube Twitter Linkedin
Facebook YouTube Twitter Linkedin

Blog

20 June 2018

Why do we need to take mental wellbeing as seriously as physical health at work?

Mental wellbeing is integral to the health and functioning of the workforce, the compromise of which can have serious social and financial ramifications - but what actions can employers take to promote mental wellbeing?  


29 May 2018

CANTAB digital neuroscience technology: revolutionising the detection of cognitive impairment in patients with multiple sclerosis

Cognitive dysfunction is a leading cause of disability in multiple sclerosis (MS), yet practical restraints mean it often goes unassessed in routine clinical care. Promising new research, published in Frontiers in Neurology, suggests the Cambridge Neuropsychological Test Automated Battery (CANTAB) may offer a brief and sensitive technological solution.

27 April 2018

7 tests for assessing cognition in early Alzheimer’s disease

With rising life-expectancy, the number of cases of dementia and related disorders is increasing. In attempts to tackle the pandemic, treatment trials are moving earlier in the disease process. CANTAB offers a battery of tests specially targeted at assessing cognition in early Alzheimer’s disease (AD), and the associated effects on cognition with drug action

12 April 2018

A solution for improving recruitment into early Alzheimer’s disease clinical trials

Screening patients into early stage Alzheimer’s trials can be costly and time-consuming. Kenton Zavitz, PhD, Director of Clinical Affairs proposes a potential solution for improving recruitment into clinical trials. 

9 April 2018

The challenge of detecting early Alzheimer’s disease for clinical trials

In this post, Director of Clinical Affairs, Dr Kenton Zavitz, looks at the challenge of recruiting the correct patients into Alzheimer's disease trials.

7 April 2018

Exploring participant-level trajectories of cognitive performance in patients with schizophrenia

Cambridge Cognition and Boehringer Ingelheim have been investigating cognitive performance among patients with schizophrenia, with a view to improving future pro-cognitive drug trial designs. Our Director of Neuroscience, Dr Kiri Granger, presented the latest findings at ISCTM and SIRS.

6 April 2018

Affective face processing in schizophrenia: disorder-specific or transdiagnostic deficit?

Our recent review of meta-analyses concluded that facial emotion recognition deficits are common across a range of psychiatric, neurological and developmental disorders.

Our Senior Scientist, Dr Jack Cotter, presented the latest findings at Schizophrenia International Research Society (SIRS) conference.